Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Huakan Bio

Request full access

The biomimetic 3D technology product that focuses on solving customized, large-scale, automated, and high-quality stem cell culture and expansion processes

Dongcheng District, ChinaFounded 2018Biotech & Life Sciences

About Huakan Bio

Beijing Huakan Biotechnology Co., Ltd., also known as CytoNiche, is a company that emerged in 2018 from a research team at Tsinghua University's School of Medicine. The company was co-founded by CEO Liu Wei, Chief Scientist Professor Du Yanan, and Dr. Yan Xiaojun, who is the CTO. The core technology, which originated from scientific and technological achievements at Tsinghua University, is centered on a proprietary 3D micro-scaffold technology.

Huakan Bio operates in the upstream biopharmaceutical market, providing solutions for the large-scale manufacturing of cells. The company's business model has evolved from solely selling products to a more integrated "product + service" approach, establishing a Contract Development and Manufacturing Organization (CDMO) platform. Its client base includes companies and research institutions in gene and cell therapy, vaccine production, protein product development, and regenerative medicine. Huakan Bio also serves emerging markets such as organoids and cultivated meat.

The company’s flagship offering is the 3D FloTrix® automated process system for large-scale cell production. This system encompasses a suite of products, including the proprietary 3D TableTrix® Microcarrier Tablets. These dissolvable microcarriers are a key component, having received pharmaceutical excipient qualifications from both the U.S. FDA and China's NMPA. The full system includes bioreactors, cell harvesting equipment, and reagents designed to automate the entire cell production workflow from inoculation and expansion to harvesting and formulation. This technology significantly reduces the need for manual labor, production space, and material consumption compared to traditional 2D cell culture methods.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Dongcheng District, China
Employees
1
Open positions
None listed
Dealroom signal
57.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Technology
3D Technology, Deep Tech
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jul 2023 $10K — brics-inno.com ↗
SERIES B✓Equity / VC Mar 2022 $41M $165M Sinopharm Healthcare Fund · Aibo · Gaorong Ventures · Yijing Capital ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Huakan Bio website traffic

Latest recorded traffic for Huakan Bio is 2K monthly website visits, up 81.8% over the last three months. Huakan Bio's team grew 0% over the past year.

Latest monthly visits2K 3-month web change+81.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Huakan Bio in the Dongcheng District ecosystem

Live from Dealroom

The Huakan Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • brics-inno.com

Series A11 investors entered at this stage

  • Guoke Jiahe (Beijing) Investment Management
  • CASH Capital
  • Detong Capital
  • Sinopharm Healthcare Fund
  • Aibo
  • Gaorong Ventures
  • Yijing Capital
  • Kexing
  • Shanghai CICC Capital
  • Hongtai Fund (Shenzhen)
  • Yuanhui Capital

Other known investors2 additional known investors

  • Tsinghua University
  • Hongtai Aplus
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇸🇬 Singapore100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Huakan Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Huakan Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.